Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17 clinical trials
Intermittent Selumetinib for Uveal Melanoma

The purpose of this study is to find out what effects, good and/or bad, intermittent dosing of the drug Selumetinib will have on subjects with uveal melanoma. Selumetinib is a drug that blocks

alopecia
platelet count
liver disease
mek inhibitor
measurable disease
  • 0 views
  • 27 Mar, 2021
  • 3 locations
  • 0 views
  • 27 Jan, 2021
  • 29 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphomas or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

graft-versus-host disease
measurable disease
neutrophil count
radiopharmaceutical therapy
nitrosoureas
  • 997 views
  • 01 Aug, 2021
  • 114 locations
Selumetinib and Olaparib in Solid Tumors

selumetinib and olaparib that can be given to patients who have solid tumors that are advanced or recurrent (has returned after treatment). The goal of Phase 2 is to learn if the highest tolerable dose

KRAS
measurable disease
mammogram
  • 11 views
  • 25 Jan, 2021
  • 1 location
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours

Phase I and II study of the MEK inhibitor Selumetinib given twice daily on 5 out of 7 days in children with NF1 and inoperable plexiform neurofibromas or progressive/relapsed optic pathway

tumor resection
ejection fraction
MRI
plexiform neurofibroma
gilbert disease
  • 48 views
  • 18 Jun, 2021
  • 2 locations
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

This is a phase I, open-label, dose-escalation study to determine the MTD of selumetinib when combined with the standard dose of azacitidine. Treatment will begin within 28 days of screening

direct bilirubin
essential thrombocythemia
thrombocytosis
ruxolitinib
thrombocytopenia
  • 13 views
  • 21 May, 2021
  • 1 location
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase 3 trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously

astrocytoma
hypertension
hypertensive medications
low grade glioma
vincristine
  • 14 views
  • 01 Aug, 2021
  • 52 locations
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors

In this research study the researchers want to learn more about the effects (both good and bad) the study drug selumetinib has on participants with neurofibromatosis type II (NF2) related tumor

multiple meningiomas
monoclonal antibodies
selumetinib
biological factors
measurable disease
  • 580 views
  • 28 Jul, 2021
  • 1 location
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

This pilot phase II trial studies how well selumetinib works in treating patients with neurofibromatosis type 1 and cutaneous neurofibromas. Selumetinib may stop the growth of tumor cells by

growth factor
peg-intron
gilbert disease
vascular endothelial growth factor
absolute neutrophil count
  • 269 views
  • 06 Mar, 2021
  • 3 locations
International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia

This trial is to investigate the combination of selumetinib and dexamethasone in the treatment of acute lymphoblastic leukaemia (ALL) in both adults and children. Phase I is to find the most

dexamethasone
graft versus host disease
  • 80 views
  • 29 Jan, 2021
  • 21 locations